Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHAACHI GUPTA

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1467649368
CMS profile
1381570
Location
PALM SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,230.30

131 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,230.30 131

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 131 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHAACHI GUPTA

NPI 1467649368 · CMS profile ID 1381570

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PALM SPRINGS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 131 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467649368?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHAACHI GUPTA, NPI 1467649368, CMS profile ID 1381570. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 131 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467649368?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SHAACHI GUPTA, NPI 1467649368, CMS profile ID 1381570. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 131 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467649368?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SHAACHI GUPTA, NPI 1467649368, CMS profile ID 1381570, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 131 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1467649368?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

131 matching records · $2,230.30 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 131 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 131.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $16.9507/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914686617 CMS
AstraZeneca Pharmaceuticals LP $0.8707/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915138931 CMS
Pharmacyclics LLC, an AbbVie Company $12.3007/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 890340805 CMS
Medtronic, Inc. $31.8707/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930736697 CMS
Heron Therapeutics, Inc. $16.0407/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 910504867 CMS
Janssen Biotech, Inc. $16.3007/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885782717 CMS
AstraZeneca Pharmaceuticals LP $23.3107/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915483861 CMS
Novartis Pharmaceuticals Corporation $14.5507/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893719417 CMS
Seagen Inc. $19.9007/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904103533 CMS
BeiGene USA, Inc. $16.1607/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940795031 CMS
Celgene Corporation $9.6107/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932723787 CMS
Celgene Corporation $0.4107/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932723789 CMS
Janssen Biotech, Inc. $16.0507/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885782723 CMS
Janssen Biotech, Inc. $18.8907/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885782706 CMS
Ipsen Biopharmaceuticals, Inc $19.2606/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893392883 CMS
Janssen Biotech, Inc. $16.4306/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885782677 CMS
Merck Sharp & Dohme LLC $18.0506/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944185243 CMS
PFIZER INC. $18.0706/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949175099 CMS
E.R. Squibb & Sons, L.L.C. $22.6606/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932723777 CMS
Celgene Corporation $18.0606/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932723985 CMS
Astellas Pharma US Inc $13.3906/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940198679 CMS
Celgene Corporation $0.8005/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932723769 CMS
Celgene Corporation $22.7105/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932723771 CMS
E.R. Squibb & Sons, L.L.C. $29.9705/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932723779 CMS
Daiichi Sankyo Inc. $18.1705/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930841311 CMS
Lilly USA, LLC $13.5605/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918366853 CMS
Amgen Inc. $20.8505/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939899931 CMS
GENZYME CORPORATION $25.3805/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939003109 CMS
Seagen Inc. $16.2605/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904103507 CMS
PFIZER INC. $14.7405/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949496207 CMS
Foundation Medicine, Inc. $11.7305/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924043211 CMS
Novartis Pharmaceuticals Corporation $11.7205/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893719415 CMS
Seagen Inc. $13.1705/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904103501 CMS
Celgene Corporation $0.1805/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932723773 CMS
Celgene Corporation $8.6605/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932723775 CMS
Daiichi Sankyo Inc. $19.5605/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930846891 CMS
Merck Sharp & Dohme LLC $19.2405/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944176917 CMS
Janssen Biotech, Inc. $5.2505/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885782687 CMS
Janssen Biotech, Inc. $13.4205/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885782741 CMS
Merck Sharp & Dohme LLC $15.0305/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944168241 CMS
Merck Sharp & Dohme LLC $14.3404/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944168253 CMS
Lilly USA, LLC $24.2804/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918282267 CMS
PFIZER INC. $16.1804/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949120151 CMS
JAZZ PHARMACEUTICALS INC. $23.1604/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951349595 CMS
Janssen Biotech, Inc. $13.3004/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885782683 CMS
Janssen Biotech, Inc. $1.1304/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885782735 CMS
SECURA BIO, INC. $12.6704/14/2022 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 964232941 CMS
Kite Pharma, Inc. $11.8404/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920061905 CMS
Janssen Biotech, Inc. $20.7704/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885782729 CMS
Sun Pharmaceutical Industries Inc. $17.3304/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947912307 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,624.73 153
PY2020 $1,143.42 65
PY2021 $1,713.96 102
PY2022 $2,230.30 131
PY2023 $3,359.49 161
PY2024 $5,179.40 213
PY2025 $8,338.26 256

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $102,872.71 44
PY2024 Principal investigator $37,792.96 14
PY2023 Principal investigator $131,576.78 93
PY2022 Recipient $1,908.00 1
PY2022 Principal investigator $113,723.00 68
PY2021 Principal investigator $11,504.47 5
PY2020 Principal investigator $20,000.04 5
PY2019 Recipient $5,846.00 1
PY2019 Principal investigator $51,977.35 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739395
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 12/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233743038
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739393
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739391
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233743034
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 10/29/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233743036
Principal investigator 1 Incyte Corporation $956.00 10/15/2025 Non-covered Recipient Entity
SANSUM CLINIC : SANTA BARBARA
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1240584481
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 10/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233743032
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739363
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739365
Principal investigator 1 Merck Sharp & Dohme LLC $34,811.71 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists - East
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan sac-TMT, MK-2870 as a Monotherapy and in Combination with PembrolizumabMK-3475 Versus Treatment of Physician's Choice in Participants With Previously Untr No dispute reported 06/30/2026 1232922948
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742840
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742842
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742844
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742846
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742848
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $900.00 08/06/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742850
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739367
Principal investigator 1 Incyte Corporation $956.00 07/15/2025 Non-covered Recipient Entity
SANSUM CLINIC : SANTA BARBARA
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1240584477
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739369
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739371
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $550.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739373
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739375
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $550.00 05/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739377
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742834
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742836
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742838
Principal investigator 1 Eli Lilly and Company $1,998.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS
POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY No dispute reported 06/30/2026 1187882400
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739379
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $550.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739381
Principal investigator 1 Incyte Corporation $956.00 04/15/2025 Non-covered Recipient Entity
HONOR HEALTH VIRGINIA G. PIPER CANCER CARE NETWORK
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1240538457
Principal investigator 1 Genentech, Inc. $300.00 04/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211649599
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739383
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $550.00 03/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739385
Principal investigator 1 Genentech, Inc. $850.00 03/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211649576
Principal investigator 1 Eli Lilly and Company $2,664.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
POSTMONARCH: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS FULVESTRANT TO PLACEBO PLUS FULVESTRANT IN PARTICIPANTS WITH HR+, HER2-, ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK4 & 6 INHIBITOR AND ENDOCRINE THERAPY No dispute reported 06/30/2026 1187891678
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,500.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742830
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $18,500.00 03/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233742832
Principal investigator 1 Genentech, Inc. $2,575.00 02/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211649583
Principal investigator 1 Genentech, Inc. $1,500.00 02/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211649603
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $500.00 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739387
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $550.00 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233739389
Principal investigator 1 Genentech, Inc. $2,000.00 01/21/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211649612
Principal investigator 1 Incyte Corporation $956.00 01/15/2025 Non-covered Recipient Entity
HONOR HEALTH VIRGINIA G. PIPER CANCER CARE NETWORK
A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) No dispute reported 06/30/2026 1240538452